{"organizations": [], "uuid": "9ff76179ec196422fdf1762bd5669f3534b312e0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180302.html", "section_title": "Archive News &amp; Video for Friday, 02 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-stada-says-ema-starts-evaluation-o/brief-stada-says-ema-starts-evaluation-of-resubmitted-pegfilgrastim-application-idUSASM000K03", "country": "US", "domain_rank": 408, "title": "BRIEF-Stada Says EMA Starts Evaluation Of Resubmitted Pegfilgrastim Application", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.008, "site_type": "news", "published": "2018-03-02T16:38:00.000+02:00", "replies_count": 0, "uuid": "9ff76179ec196422fdf1762bd5669f3534b312e0"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-stada-says-ema-starts-evaluation-o/brief-stada-says-ema-starts-evaluation-of-resubmitted-pegfilgrastim-application-idUSASM000K03", "ord_in_thread": 0, "title": "BRIEF-Stada Says EMA Starts Evaluation Of Resubmitted Pegfilgrastim Application", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "stada", "sentiment": "negative"}, {"name": "stada arzneimittel ag", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "amgen", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 2 (Reuters) - Stada:\n* DGAP-NEWS: STADA ARZNEIMITTEL AG: EMA STARTED THE EVALUATION OF RESUBMITTED MARKETING AUTHORISATION APPLICATION FOR BIOSIMILAR PEGFILGRASTIM\n* ‍EUROPEAN MEDICINES AGENCY (EMA) HAS ACCEPTED REGULATORY RESUBMISSION OF ITS PROPOSED BIOSIMILAR TO AMGEN’S NEULASTA​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-02T16:38:00.000+02:00", "crawled": "2018-03-03T17:31:56.007+02:00", "highlightTitle": ""}